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A bs tr ac t
Background
The myelodysplastic syndromes are a group of hematologic disorders that often 
evolve into secondary acute myeloid leukemia (AML). The genetic changes that un-
derlie progression from the myelodysplastic syndromes to secondary AML are not 
well understood.
Methods
We performed whole-genome sequencing of seven paired samples of skin and bone 
marrow in seven subjects with secondary AML to identify somatic mutations specific 
to secondary AML. We then genotyped a bone marrow sample obtained during the 
antecedent myelodysplastic-syndrome stage from each subject to determine the pres-
ence or absence of the specific somatic mutations. We identified recurrent mutations 
in coding genes and defined the clonal architecture of each pair of samples from the 
myelodysplastic-syndrome stage and the secondary-AML stage, using the allele bur-
den of hundreds of mutations.
Results
Approximately 85% of bone marrow cells were clonal in the myelodysplastic-syndrome 
and secondary-AML samples, regardless of the myeloblast count. The secondary-AML 
samples contained mutations in 11 recurrently mutated genes, including 4 genes that 
have not been previously implicated in the myelodysplastic syndromes or AML. In 
every case, progression to acute leukemia was defined by the persistence of an an-
tecedent founding clone containing 182 to 660 somatic mutations and the outgrowth 
or emergence of at least one subclone, harboring dozens to hundreds of new mutations. 
All founding clones and subclones contained at least one mutation in a coding gene.
Conclusions
Nearly all the bone marrow cells in patients with myelodysplastic syndromes and sec-
ondary AML are clonally derived. Genetic evolution of secondary AML is a dynamic 
process shaped by multiple cycles of mutation acquisition and clonal selection. Recur-
rent gene mutations are found in both founding clones and daughter subclones. 
(Funded by the National Institutes of Health and others.)
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T he myelodysplastic syndromes, a het-erogeneous group of diseases characterized by ineffective hematopoiesis, are the most 
common cause of acquired bone marrow failure in 
adults.1 Secondary acute myeloid leukemia (AML) 
develops in approximately one third of persons 
with myelodysplastic syndromes.2 Clinical discrim-
ination between the myelodysplastic syndromes 
and secondary AML currently rests predominantly 
on cytomorphologic analysis, since patients with 
myelodysplastic syndromes have dysplastic hema-
topoiesis and a myeloblast count of less than 20%, 
whereas those with a myeloblast count of 20% or 
more have AML. Although considerable overlap ex-
ists between the spectrum of cytogenetic and mo-
lecular lesions seen in the two disorders, there re-
mains uncertainty among patients, insurers, and 
funding agencies about whether the myelodysplas-
tic syndromes are actually cancers.3
The genetic events underlying the progression 
from cellular dysplasia to cancer have been studied 
extensively in epithelial tissues (e.g., from the colon 
and oropharynx),4-6 but less is known about the 
genetic progression of the myelodysplastic syn-
dromes to secondary AML. Candidate-gene rese-
quencing has identified several genes that have 
recurrent mutations during the evolution from the 
myelodysplastic syndromes to secondary AML 
(e.g., FLT3, NPM1, RUNX1, TP53, and NRAS),7-15 but 
our understanding of the total number and clonal 
distribution of mutations in this disease is limited. 
We used whole-genome sequencing to discover 
somatic mutations in bone marrow samples ob-
tained from seven subjects with secondary AML 
and determined whether these mutations were 
present in paired samples obtained during the 
antecedent myelodysplastic-syndrome stage. We 
used this information to define the proportion of 
clonal cells and genetic architecture at the time of 
diagnosis of a myelodysplastic syndrome and pro-
gression to secondary AML.
Me thods
Methods are described in detail in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org. In brief, bone marrow biopsy 
specimens were obtained from seven subjects, all 
of whom provided written informed consent on a 
form that contained specific language authorizing 
whole-genome sequencing. Myeloblasts were en-
riched by means of cell sorting. Paired-end DNA 
libraries from bone marrow samples (for second-
ary AML) and normal skin samples were sequenced 
on the Illumina HiSeq 2000 and Genome Analyzer 
IIx. Aligned reads were analyzed to detect puta-
tive somatic mutations, as described previously.16 
Somatic-mutation predictions were validated with 
the use of solid-phase capture, followed by deep 
sequencing of skin, myelodysplastic-syndrome, and 
secondary-AML samples. Mutations in one subject 
(UPN266395) have been reported previously.17 
Array-based profiling of DNA copy number and 
gene expression were performed, as described 
previously.18 Sequence and microarray data have 
been deposited in the database of Genotypes 
and Phenotypes (dbGaP) of the National Center 
for Biotechnology Information (accession number, 
phs000159.v3.p2).
R esult s
Whole-Genome Sequencing and Capture 
Validation
We performed whole-genome sequencing using 
paired-end reads generated from DNA libraries pre-
pared from secondary-AML samples and matched 
skin samples from seven subjects with antecedent 
de novo myelodysplastic syndromes (Table 1). Dip-
loid genome coverage was more than 95% for the 
secondary-AML samples and 97% for the skin sam-
ples (Table 1 in the Supplementary Appendix). 
Putative somatic mutations were called and pri-
oritized into nonoverlapping tiers, as described 
previously.16 To validate somatic mutations and 
measure mutant allele frequencies, we designed 
custom solid-phase long-oligonucleotide arrays for 
each subject and used them to capture regions of 
the genome containing putative single-nucleotide 
variants (SNVs, or point mutations) and insertions 
or deletions (indels). For each subject, a trio of sam-
ples was analyzed (normal skin, bone marrow 
obtained during the antecedent myelodysplastic-
syndrome stage, and bone marrow obtained dur-
ing the secondary-AML stage). The captured DNA 
was sequenced to provide an average of 640 reads 
at the sites of validated mutations (Table 1 in the 
Supplementary Appendix). In each genome, we 
validated 304 to 872 somatic point mutations and 
0 to 2 indels in tier 1 (i.e., the tier consisting of 
changes in the amino acid coding regions of an-
notated exons, consensus splice-site regions, and 
RNA genes) (Tables 2 and 3 in the Supplementary 
Appendix). The enrichment of myeloblasts by 
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means of cell sorting had no major effect on mea-
surement of the mutant allele burden (Fig. 1 in the 
Supplementary Appendix).
Recurrent Gene Mutations
We first focused on tier 1 mutations with predict-
ed translational consequences (i.e., whole-gene de-
letions, indels, missense, nonsense, frameshift, or 
splice-site mutations). There were 17 to 32 validated 
point mutations or indels (mean, 24) per secondary-
AML genome in 168 genes among the seven sam-
ples (Table 3 in the Supplementary Appendix). Most 
of these genes did not have recurrent mutations, 
suggesting that many of the mutations were ran-
domly acquired and not causally related to the 
pathogenesis of the myelodysplastic syndromes. 
Two recurrently mutated genes were detected in 
two samples each: loss-of-function mutations in a 
known myeloid-tumor suppressor, RUNX1, and two 
somatic missense mutations in UMODL1 (Table 2). 
UMODL1 was recently reported to be mutated in pa-
tients with multiple myeloma and those with ovar-
ian cancer.19,20 UMODL1 messenger RNA (mRNA) 
was expressed in normal CD34+ progenitor cells 
and in secondary-AML cells from our seven sub-
jects, and the two mutations occurred in regions of 
UMODL1 encoding conserved domains (T533P in 
a calcium-binding epidermal-growth-factor–like 
domain and V882M in a sea-urchin sperm protein, 
enterokinase, and agrin [SEA] domain).21
To extend these results, we compared the mu-
tations with translational consequences in myelo-
dysplastic-syndrome and secondary AML samples 
with mutations identified in 200 de novo AML 
samples (50 subjected to whole-genome sequenc-
ing and 150 to whole-exome sequencing). We 
identified 10 genes that were mutated in one sec-
ondary-AML sample and in at least 3 of 200 AML 
samples (>1%) (Table 2). Seven of these genes are 
known to have recurrent mutations in AML. Four 
genes with recurrent mutations (including UMODL1) 
have not previously been implicated in the myelo-
dysplastic syndromes or AML. A specific codon in 
U2AF1 harbored missense mutations in multiple 
AML samples, suggesting that these mutations 
may cause gain of function. Supporting this hy-
pothesis is our recent report17 that the S34F substi-
tution in U2AF1 (affected by a missense mutation) 
enhances alternative mRNA splicing in vitro. The 
X-chromosome gene STAG2 was also recurrently 
mutated. All STAG2 mutations that we observed in 
this study are predicted to cause protein trunca-
tion (H738fs in secondary AML and all 4 nonsense 
or frameshift mutations in AML). In addition, 
STAG2 is deleted in AML and other cancers.22,23 
Taken together, these results suggest that STAG2 
loss of function probably contributes to the patho-
genesis of the myelodysplastic syndromes and 
AML. Although STAG2 inactivation was recently 
reported to cause aneuploidy in glioblastoma and 
Table 1. Characteristics of Seven Subjects with Myelodysplastic Syndromes (MDS) and Progression to Secondary Acute 
Myeloid Leukemia (sAML).
UPN* Sex














461282 M 65 2.0 6 69 Complex Complex 22 58 67
667720 F 66 1.0 10 29§ Normal Normal 22 21 24
610184 F 45 1.0 0 38 Complex Complex 5 10 20
182896 M 75 1.0 0 51 Complex Complex 32 35 40
266395 M 65 1.0 7 66 Normal Normal 1 3 11
288033 F 31 1.0 13 43 Normal Normal 1 1 12
298273 M 26 2.0 18 35 Normal Normal 4 4 18
* UPN denotes unique patient number.
† The International Prognostic Scoring System (IPSS) ranges from 0 to 3.5, with higher scores indicating a worse prognosis.
‡ Values are the intervals between tissue banking of MDS samples and sAML samples.
§ This analysis was performed by means of flow cytometry.
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colorectal-cancer cell lines,23 the subjects with 
STAG2 mutations in our study had normal karyo-
types.
Singleton mutations (i.e., mutations that are not 
recurrent) may also be important in the patho-
genesis of the myelodysplastic syndromes. Overall, 
the nonrecurrent tier 1 mutations implicate mutant 
proteins in 1 of 11 biologic pathways24 that are 
relevant for cancer pathogenesis, and nearly all 
these pathways were affected in all seven samples 
(Fig. 2 in the Supplementary Appendix). Tier 1 
mutations were not substantially enriched in any 
single pathway (data not shown).24
Clonality of Myelodysplastic Syndromes  
and Secondary AML
The clinicopathological diagnosis of the myelo-
dysplastic syndromes requires a finding of less 
than 20% myeloblasts (morphologically defined 
malignant cells) in the bone marrow. However, 
data from single-nucleotide-polymorphism (SNP) 
array and single-gene resequencing studies have 
suggested that the clonal population of cells in the 
myelodysplastic syndromes can be greater than 
20%.18,25,26 In this study, we used capture sequenc-
ing data to accurately measure the prevalence of 
clonal cells in myelodysplastic-syndrome samples. 
We calculated the mutant allele frequencies for all 
validated somatic SNVs (adjusted for chromosome 
copy number) and performed an unsupervised clus-
tering analysis to define mutation clusters.27 Each 
myelodysplastic-syndrome and secondary-AML ge-
nome contained a founding clone of cells, defined 
as the mutation cluster (containing 182 to 660 so-
matic SNVs) that had the highest mutant allele bur-
den at the myelodysplastic-syndrome and second-
ary-AML stages (cluster 1 in Fig. 1A, and Fig. 5 in 
the Supplementary Appendix). We estimated max-
imum tumor clonality as twice the average mutant 
allele frequency of the founding clone (since all 
mutations were present once per diploid genome 
after copy-number correction). In all cases, the ma-
jority of unfractionated bone marrow cells (up to 
92.7%) in the myelodysplastic-syndrome samples 
were clonal and indistinguishable from the cells 
in the secondary-AML samples, even with a my-
eloblast count of less than 5% (Fig. 1B). Although 
these results confirm previous observations that 
the myeloblast count can underestimate the size 
of the clonal population in myelodysplastic syn-
dromes,18,25,26 they also suggest that when the 
entire genome is interrogated for mutations, clon-
al hematopoiesis involving most of the bone mar-
row appears to be the rule even in early-stage my-
elodysplastic syndromes.
To assess the clonality of copy-number altera-
tions, we designed capture probes spanning het-
erozygous SNPs that were present in the skin 
samples and deleted or retained in the bone mar-
row samples on the basis of SNP arrays and data 
from whole-genome sequencing (Table 4 in the 
Supplementary Appendix). We determined the pro-
portion of read counts containing alleles present in 
the skin samples that were retained in the myelo-
dysplastic-syndrome and secondary-AML samples. 
The prevalence of the retained alleles in the skin 
samples was approximately 50%, as expected for 
heterozygous SNPs. The prevalence of these alleles 
in the myelodysplastic-syndrome and secondary-
AML samples diverged from 50% and was pro-
portionate to the percentage of cells harboring a 
deletion (Table 5 in the Supplementary Appendix). 
Clustering of the data regarding copy-number al-
terations largely recapitulated the SNV clusters for 
these subjects (Fig. 1C, and Fig. 7 in the Supple-
mentary Appendix). However, unique clones (i.e., 
Table 2. Genes with Recurrent Mutations in De Novo 
AML Detected in MDS and sAML Genomes.
Gene and Mutation*




CDH23 (1235insL)† No Yes
NPM1 (W288fs)‡ Yes Yes
PTPN11 (G60R)‡ No Yes
RUNX1
G170fs No Yes
del(21) (q22.11) Yes Yes
SMC3 (e8-1 splice)† Yes Yes
STAG2 (H738fs) Yes Yes
TP53 (V272M) Yes Yes




WT1 (D436E) No Yes
ZSWIM4 (P818A)† Yes Yes
* The mutation is listed according to the amino acid posi-
tion. The abbreviation sAML denotes secondary AML.
† This mutation has not previously been reported in MDS 
or AML.
‡ The same codon was affected in more than one subject.
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unique populations of cells defined by the muta-
tion clusters they contained) were identified by 
both approaches, suggesting that these types of 
data provide complementary views of clonal evo-
lution. Our methods do not capture changes in 
DNA methylation, which are known to be present 
in myelodysplastic-syndrome genomes,28 suggest-
ing that there may be additional layers of clonal 
complexity that we have not detected.
All seven samples were oligoclonal at the sec-
ondary-AML stage and were monoclonal in only 
two cases at the myelodysplastic-syndrome stage 
(Fig. 1D). In the first subject (UPN461282), we 
identified five distinct mutation clusters that col-
lectively defined the clonal genetic progression of 
this tumor (Fig. 1A). Two clones were present in 
the myelodysplastic-syndrome sample. A single cell 
in clone 2, which contained cluster 1 and 2 mu-
tations, moved forward and by acquisition of clus-
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Figure 1. Oligoclonality of Genomes for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia 
(sAML) in One Subject.
In Panel A, the allele frequencies of all validated mutations in Subject UPN461282 are shown at the MDS stage and 
after progression to sAML. Mutant allele frequencies were adjusted for chromosomal copy number. Unsupervised 
clustering of individual mutations identified five distinct mutation clusters. Panel B shows similar total bone marrow 
clonality (the proportion of cells containing the founding mutations) in MDS and sAML (P = 0.57), despite myeloblast 
counts ranging from 0 to 69%. In Panel C, the frequency of reads supporting the retained (A) allele in regions of 
copy-number alteration is shown in MDS and sAML. Cells containing two clusters of clonal copy-number changes 
increase in number between MDS and sAML (yellow and orange data points), whereas a subclone containing a distal 
5(q) deletion is lost during progression from MDS to sAML (blue data points). The founding clone contains del(17), 
del(20q), and cluster 1 single-nucleotide variants (SNVs) (yellow data points in Panels A and C), whereas a subclone 
also contains del(5), monosomy 17, and cluster 2 SNVs (orange data points in Panels A and C). Dashed lines indicate 
the expected A allele frequency for heterozygous SNPs that are not in deleted segments. Panel D shows that MDS 
and sAML are oligoclonal, with a mean of 2.4 clones in MDS and 3.1 in sAML (P = 0.047). The abbreviation del(17) 
denotes telomeric chromosome 17 deletions, del(20q) denotes del(20)(q11.21q13.13), and del(5) denotes interstitial 
deletions on the short and long arms of chromosome 5.
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clones that were present only in the secondary-
AML sample. Collectively, the data suggest that the 
evolution of this tumor proceeded sequentially 
from cells with cluster 1 mutations to cells con-
taining cluster 1 to 5 mutations, with each new 
clone carrying forward all the preexisting patho-
genic and nonpathogenic mutations (Fig. 2A). The 
other six tumors also conformed to linear models 
of clonal evolution (Fig. 5 in the Supplementary 
Appendix), although analysis at the single-cell level 
may reveal more complex patterns in some cases.
The secondary-AML genomes contained 304 to 
872 somatic SNVs (Table 2 in the Supplementary 
Appendix). It is likely that most of these mutations 
are irrelevant to the pathogenesis of the disease. 
Consistent with this notion is the observation that 
the number of somatic SNVs per genome tier 
tended to be proportionate to the tier size (as ex-
pected by chance), suggesting that the vast major-
ity of mutations were random background muta-
tions (Fig. 3A in the Supplementary Appendix). We 
observed that most of the mutations in each sec-
ondary-AML sample were present in the paired 
myelodysplastic-syndrome sample, and there was 
a subset of secondary-AML–specific mutations. 
As expected, the proportion of secondary-AML –
specific mutations was smaller in the four sub-
jects who had rapid progression to secondary AML 
(<6 months) than in the three subjects with slower 
progression (>20 months). An average of 6.7% of 
all mutations were specific to secondary AML in 
the subjects with rapid progression, as compared 
with 37.8% of secondary-AML–specific mutations 
in the subjects with slow progression (P<0.05) (Fig. 
3B in the Supplementary Appendix). The spectrum 
of transition and transversion mutations in the 
myelodysplastic-syndrome founding clone was 
similar in all seven subjects (Fig. 4 in the Supple-
mentary Appendix). The most common substitu-
tion was a C·G→T·A transition, as seen in other 
cancer genomes.29,30 Two subjects (who had been 
treated with decitabine for 4 to 11 months, after 
the diagnosis of a myelodysplastic syndrome and 
before the progression to secondary AML) had a 
significant increase in the frequency of secondary-
AML–specific C→G transversions in their second-
ary-AML samples, whereas two subjects who were 
not treated with decitabine did not have a similar 
increase (Fig. 4 in the Supplementary Appendix). 
We could not identify a sequence-specific context 
for these transversions.
Even though the mutations driving clonal out-
growth at each stage are not known, the founding 
clone in the seven myelodysplastic-syndrome sam-
ples (containing 182 to 660 mutations) persisted in 
all seven secondary-AML samples and included at 
least one tier 1 mutation. The founding clones ac-
quired at least one new tier 1 mutation with pre-
dicted translational consequences during the gen-
eration of secondary-AML–specific clusters (Fig. 5 
in the Supplementary Appendix). Genes with re-
current mutations were detected in both founding 
clones and daughter subclones (Fig. 2B).
Discussion
Using next-generation sequencing, we have found 
that the proportion of neoplastic bone marrow cells 
is indistinguishable in myelodysplastic-syndrome 
and secondary-AML samples, suggesting that the 
myelodysplastic syndromes are as clonal as second-
ary AML, even with a myeloblast count of zero. Al-
though clonality is not sufficient to define malig-
nant transformation, it is a cardinal manifestation 
of most human cancers, and our findings suggest 
that the myelodysplastic syndromes and secondary 
AML are both highly clonal hematologic cancers.31 
Analysis of the proportion of mutant cells in sam-
ples obtained from the same subject before and af-
ter progression to secondary AML allowed us to 
compare the clonal architecture and genes that 
were mutated in order to gain insight into the ge-
netics of these diseases. Robust detection of muta-
tion clusters was possible because hundreds of mu-
tations per genome were identified by whole-genome 
sequencing, and the allele burdens were quantified 
by deep resequencing at two time points. If we had 
analyzed only the secondary-AML samples or only 
the tier 1 (i.e., exomic) variants, this complexity 
could not have been elucidated. In the samples 
from all seven subjects, the secondary-AML ge-
nomes were oligoclonal. The preexisting myelodys-
plastic-syndrome founding clone always persisted 
in secondary AML, although it was outcompeted by 
daughter subclones in some cases. With the acqui-
sition of each new set of mutations, all the preexist-
ing mutations were carried forward, resulting in 
subclones that contained increasing numbers of 
mutations during evolution. On the basis of our 
experimental design, we cannot exclude the pos-
sibility that there were additional subclones in the 
myelodysplastic-syndrome samples that were not 
present in the secondary-AML samples, and one ge-
nome (UPN298273) suggests that this could occur.
A unique aspect of the biology of leukemia is 
that hematopoietic cells freely mix and recirculate 
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between the peripheral blood and the bone mar-
row. Clones that persist and grow over time must 
retain the capacity for self-renewal. Mutations in 
new clones must confer a growth advantage for 
them to successfully compete with ancestral 
clones. The result is that these secondary-AML 
samples are not monoclonal but are instead a mo-
saic of several genomes with unique sets of muta-
tions; this mosaic is shaped by the acquisition of 
serial mutations and clonal diversification. Simi-
B Changes in Mutation-Cluster Sizes in Seven Subjects

















































































































Figure 2. Clonal Progression from Myelodysplastic Syndrome (MDS) to Secondary Acute Myeloid Leukemia (sAML).
Panel A shows a model summarizing clonal evolution from the MDS stage to the sAML stage in Subject UPN461282. 
Cells in clone 1 contain cluster 1 mutations. Clone 1 (yellow) is characterized by 323 somatic single-nucleotide variants 
(SNVs), which were present in approximately 74% of the bone marrow cells. Cells in clone 2 (orange) originated from a 
single cell in clone 1 (since all cluster 1 mutations are heterozygous and present in nearly all sAML cells) and therefore 
contain all cluster 1 and 2 mutations. This clone became dominant in the sAML sample, in which three subsequent 
subclones evolved through serial acquisition of SNVs. The last clone to emerge (comprising 14% of the bone marrow 
cellularity in sAML) may contain SNV clusters 1 to 5 or only clusters 1, 2, 3, and 5, but the analytic approach cannot 
distinguish between these possibilities. Panel B shows the dynamic changes in the size of mutation clusters from MDS 
to sAML in all seven subjects. Each cluster contains at least one tier 1 mutation. Genes with recurrent mutations are 
detected in founding clones and daughter subclones. UPN denotes unique patient number.
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larly, recent analysis of de novo AML samples with 
the use of whole-genome sequencing showed that 
relapse after chemotherapy is associated with 
clonal evolution and acquisition of new muta-
tions.32 Analysis of individual cancer cells may 
reveal additional layers of genetic complexity. Re-
cent studies of B-cell acute lymphoblastic leukemia 
have shown that serial acquisition of cytogenetic 
abnormalities in that disease most often occurs 
through a branching hierarchy and only rarely fol-
lows a simple linear path.33,34 Extending this work 
to include the full complement of mutations dis-
covered by whole-genome sequencing will be a 
major goal for future studies of cancer genetics.
Our study has several clinical implications. 
First, the distinction between the myelodysplastic 
syndromes and secondary AML currently relies on 
manual enumeration of bone marrow myeloblasts, 
a standard that is subject to interobserver bias but 
nonetheless drives major decisions about treatment 
for patients with small differences in myeloblast 
counts. Ultimately, identifying the patterns of 
pathogenic mutations and their clonality in bone 
marrow samples from patients with myelodysplas-
tic syndromes should lead to greater diagnostic 
certainty and improved prognostic algorithms. On 
this note, two of the subjects in our study had 
progression from myelodysplastic syndromes to 
secondary AML in 1 month. This progression was 
based on an increase in the myeloblast count from 
7% to 66% in one subject and from 13% to 43% 
in the other, despite an absence of change in the 
number of clones (two in each case) and only mi-
nor increases in point mutations (<2% were gained 
during progression to secondary AML in these 
cases) when the same specimens were analyzed 
by means of next-generation sequencing. Second, 
our finding that the dominant secondary-AML 
clone was derived from a myelodysplastic-syn-
drome founding clone in all cases suggests that 
therapies targeted to these early mutations might 
be the most effective strategy for eliminating 
disease-propagating cells and improving the rate 
of response to traditional chemotherapy for pa-
tients with secondary AML.35,36 Finally, it is pos-
sible that disease progression in patients with 
myelodysplastic syndromes is driven not only by 
the presence of recurrent mutations, which have 
recently been shown to have prognostic value,37 
but also by the clone (i.e., founding vs. daughter) 
in which they arise. Coupling genotyping of my-
elodysplastic-syndrome samples for prognostically 
important mutations with analysis of the clonal 
architecture may yield more informative biomark-
ers and a better understanding of the pathogenesis 
of the myelodysplastic syndromes.
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